Endogenous Testosterone, Testosterone Treatment, and Cardiovascular Health Outcomes in Men.

Cross-sectional analyses show that lower endogenous testosterone concentrations are found in men with preexisting CVD, but larger influences are age > 70 years, higher body mass index, and medical comorbidities such as diabetes or cancer.

横断面分析显示，患有既往心血管疾病的男性中发现较低的内源性睾酮浓度，但更大的影响因素是年龄>70岁、较高的体重指数以及糖尿病或癌症等合并症。

In the United Kingdom Biobank, the largest prospective cohort study to date, lower endogenous testosterone concentrations were associated with higher risk of all-cause mortality, but not incident cardiovascular events or CVD deaths.

在迄今为止最大的前瞻性队列研究英国生物银行中，较低的内源性睾酮浓度与较高的全因死亡风险相关，但与心血管事件发生或心血管疾病死亡无关。

In an individual participant data meta-analysisof prospective cohort studies with testosterone measured using mass spectrometry, there were nonlinear associations of baseline testosterone concentrations with higher all-cause and cardiovascular mortality, with these risks increasing below thresholds of testosterone < 7.4 nmol/L (213 ng/dL) and < 5.3 nmol/L (153 ng/dL), respectively.

在一项使用质谱法测量睾酮的前瞻性队列研究的个体参与者数据荟萃分析中，基线睾酮浓度与较高的全因和心血管死亡率呈非线性关联，当睾酮浓度低于7.4 nmol/L（213 ng/dL）和5.3 nmol/L（153 ng/dL）的阈值时，这些风险增加。

In the randomized, placebo-controlledT4DM trial involving men with dysglycemia, testosterone treatment on a background of lifestyle intervention reduced risk of type 2 diabetes mellitus after 2 years.

在一项针对糖耐量异常男性的随机、安慰剂对照的T4DM试验中，生活方式干预基础上的睾酮治疗在2年后降低了2型糖尿病的风险。

The TRAVERSE cardiovascular safety trial, conducted in men with CVD or multiple risk factors, found no increased risk of major adverse cardiovascular events in men randomized to testosterone treatment vs placebo, with average follow-up of 3 years.

在有心血管疾病或多种危险因素的男性中进行的TRAVERSE心血管安全性试验发现，与安慰剂相比，随机接受睾酮治疗的男性在平均随访3年期间，主要不良心血管事件的风险没有增加。

Based on epidemiological studies, and the results of T4DM and TRAVERSE, additional studies are needed to confirm long-term cardiovascular safety, and explore possible cardiovascular benefits related to changes in body composition and cardiometabolic risk.

基于流行病学研究以及T4DM和TRAVERSE的结果，需要额外的研究来确认长期的心血管安全性，并探索与身体成分和心脏代谢风险变化相关的可能心血管益处。